Rx00064 - Cladribine


Name:
Cladribine
Rx ID:
Rx00064
Validation Level:
Phenomic Similarity:
0.716
Reference ID:
DB00242
Primary Indications:
Active hairy cell leukemia; leukemic reticuloendotheliosis; chronic lymphocytic leukemia; low-grade non-Hodgkin's lymphoma; cutaneous T-cell lymphoma
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Chronic lymphocytic leukemia; non-Hodgkin's lymphoma; acute myeloid leukemia; acute myelogenous leukemia
Common Indications:
Hairy cell leukemia
Pathways:
Purine metabolism - Homo sapiens (human); Nucleotide Metabolism; RB in Cancer; Pyrimidine metabolism - Homo sapiens (human); guanosine nucleotides <i>de novo</i> biosynthesis; Gemcitabine Pathway, Pha ...Click to show more
Drug Interactions:
Leflunomide; Natalizumab; Pimecrolimus; Roflumilast; Tacrolimus Trastuzumab;
Food Interactions:
Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00064
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
low-grade non-Hodgkin's lymphoma non-Hodgkin's lymphoma 6716 6716 6716 600.793 0 0.0
leukemic reticuloendotheliosis hairy cell leukemia 84 84 84 48034.81 0 0.0
active hairy cell leukemia hairy cell leukemia 84 84 84 48034.81 0 0.0
chronic lymphocytic leukemia non-Hodgkin's lymphoma 219 1182 6716 111.314 0 0.0
cutaneous T-cell lymphoma non-Hodgkin's lymphoma 102 102 6716 600.793 8.25E-224 2.65e-220

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
LEUKEMIC RETICULOENDOTHELIOSIS HAIRY CELL LEUKEMIA 7.71e-18 BRAF, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, HLA-DRB4, TP53
CUTANEOUS T-CELL LYMPHOMA NON-HODGKIN'S LYMPHOMA 2.06e-06 ABCB1, CYP3A4, CYP3A5, EDN1, IL6, MMP2, PRF1, SH2D1A, SLCO1B3, UNC13D

Chemical, Pharmacological and Biological Annotations


ATC Code:
L01BB04
Brands:
Leustatin; Litak; Movectro; Mylinax
Categories:
Antineoplastic Agents; Immunosuppressive Agents
ChEBI ID:
567361
PubChem ID:
20279
KEGG Drug ID:
D01370
SMILE:
NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1
InChI:
1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Organooxygen Compounds
Class:
Carbohydrates and Carbohydrate Conjugates
Subclass:
Glycosyl Compounds
Indication:
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of...
Click to show more...
Pharmacodynamics:
Cladribine is a synthetic purine nucleoside that acts as an antineoplastic agent with immunosuppressive effects. Cladribine differs structurally from deoxyadenosine only by the presence of a chlorine atom at position 2 of the purine ring, w...
Click to show more...
Description:
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. [PubChem]
Mechanism:
Cladribine is structurally related to fludarabine and pentostatin but has a different mechanism of action. Although the exact mechanism of action has not been fully determined, evidence shows that cladribine is phosphorylated by deoxycytidi...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.2055 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org